Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains
- 30 November 2005
- journal article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1726 (3), 326-327
- https://doi.org/10.1016/j.bbagen.2005.09.002
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Reduced Content of Lysyl-Phosphatidylglycerol in the Cytoplasmic Membrane Affects Susceptibility to Moenomycin, as Well as Vancomycin, Gentamicin, and Antimicrobial Peptides, in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2004
- tcaA Inactivation Increases Glycopeptide Resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2004
- Two‐component system VraSR positively modulates the regulation of cell‐wall biosynthesis pathway in Staphylococcus aureusMolecular Microbiology, 2003
- Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureusBiochimica et Biophysica Acta (BBA) - General Subjects, 2003
- Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with l-LysineThe Journal of Experimental Medicine, 2001
- The Development of Vancomycin Resistance in a Patient with Methicillin-ResistantStaphylococcus aureusInfectionNew England Journal of Medicine, 1999
- First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospitalThe Lancet, 1998
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997